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Stents for
Femoropopliteal Disease
Are Some Things Better Covered Up?*
John R. Laird, MD, Ehrin J. Armstrong, MD
Sacramento, California
Covered stents have proven useful for the treatment of
complications after endovascular interventions, particularly
vessel perforation and rupture (1). One such device (Graft-
master, Abbott Vascular, Santa Clara, California) has
received approval from the U.S. Food and Drug Adminis-
tration (FDA) through a Humanitarian Device Exemption
for the treatment of coronary artery perforation, a life-
threatening complication of percutaneous coronary inter-
vention. Covered stents have also been widely used for the
exclusion of aneurysms and pseudoaneurysms in a variety of
vascular beds. A self-expanding covered stent (Flair, CR
Bard, Tempe, Arizona) was recently shown to be superior to
balloon angioplasty for the treatment of dialysis access graft
stenosis (2).
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An evolving body of literature (3–5) also supports the use
of covered stents for the treatment of lower extremity arterial
occlusive disease. The main advantage of a covered stent in
the treatment of atherosclerotic disease is that the expanded
polytetraﬂuoroethylene (ePTFE) graft material lining the
stent serves as a barrier to neointimal in-growth, thereby
reducing the risk of in-stent restenosis. Use of a covered stent
for the treatment of ulcerated/friable or thrombotic lesions
might also reduce the risk of distal embolization. Although
covered stents therefore have many theoretical advantages,
they may also be associated with speciﬁc modes of failure (4).
First, edge restenosis can occur after covered stent place-
ment, especially if the stent is oversized. Second, covered
stents have a higher risk of thrombosis, and large thrombus
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cover side branches or important collateral pathways. If the
patient experiences subsequent stent thrombosis, there is the
possibility that he or she could present with acute limb
ischemia or symptoms that are more severe than the initial
presenting symptoms. This would be a violation of the
fundamental principal of primun non nocere. For all of these
reasons, covered stents need to be studied in carefully
designed trials and compared with their noncovered
counterparts.
The greatest experience to date with covered stents in
peripheral arterial disease is with the iCAST balloon
expandable covered stent (Atrium Medical, Hudson, New
Hampshire) and the Viabahn self-expanding covered stent
(WL Gore, Flagstaff, Arizona). The iCAST is a balloon
expandable, stainless steel stent fully encapsulated in 2
layers of ePTFE. A single-center, retrospective case series
demonstrated improved patency at 2 years with the iCAST
stent compared with bare-metal stents (BMS) for the
treatment of aortic bifurcation disease (6). In the COBEST
(Covered Versus Balloon Expandable Stent Trial) trial,
a multicenter, randomized study, the iCAST stent was
superior to balloon expandable BMS for the treatment of
complex, TransAtlantic Inter-Society Consensus class C
and D aortoiliac occlusive disease (7). A prospective,
multicenter, U.S. registry evaluating the iCAST for iliac
artery disease (iCARUS [iCast Atrium Registry Ultrasound
Study] was recently completed, and the data have been
submitted to the FDA as part of a pre-market approval
application.
The Viabahn endoprosthesis is FDA approved for the
treatment of iliac and femoral artery disease. This device
consists of a self-expanding nitinol stent encapsulated in
ePTFE. There have been several improvements in Viabahn-
covered stents over time, including the addition of a heparin
bioactive surface to reduce device thrombogenicity. The
proximal edge of this device was also contoured to decrease
the risk of proximal edge restenosis, and a lower proﬁle
delivery system was developed to decrease the sheath size
needed for delivery. The Viabahn stent graft has been used
extensively for the treatment of femoropopliteal occlusive
disease, and there are numerous publications of single and
multicenter experiences with the device (3,4). A single-center
randomized trial compared the results of the Viabahn-
covered stent versus above-knee femoropopliteal bypass
surgery with prosthetic graft material for long-segment
femoropopliteal occlusive disease (5). At the 4-year follow-
up, there was no difference between the 2 treatment strate-
gies with regard to primary or secondary patency.
The VIBRANT (Viabahn Versus Bare Nitinol Stent in
the Treatment of Long Lesion [8 cm] Superﬁcial Femoral
Artery Occlusive Disease) trial was the ﬁrst to compare
covered stents with BMS in the superﬁcial femoral artery.
This multicenter, randomized trial compared an earlier
version of the Viabahn (nonheparin bonded, no proximal
contoured edge) with bare nitinol stents for long-segment
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comes between the 2 treatment groups, with disappointing
12-month primary patency for both the Viabahn and bare
nitinol stents (53% vs. 58%; p ¼ NS). The ﬁnal results of
this study remain unpublished. The VIBRANT randomized
trial was followed by a single-arm, multicenter prospective
registry (VIPER [Viabahn Endoprosthesis With Heparin
Bioactive Surface in the Treatment of Superﬁcial Femoral
Artery Obstructive Disease]) that evaluated the heparin-
bonded Viabahn in 120 patients with long superﬁcial
femoral artery stenosis or occlusion (mean lesion length
19 cm) (8). The 12-month primary patency in VIPER was
73%, suggesting a potential favorable impact of the heparin
bioactive surface on stent patency.
In this issue of the Journal, Lammer et al. (9) present the
latest chapter in the covered stent story. They report the
results of the VIASTAR (Viabahn Endoprosthesis With
PROPATEN Bioactive Surface [VIA] Versus Bare Nitinol
Stent in the Treatment of Long Lesions in Superﬁcial
Femoral Artery Occlusive Disease) trial, a European ran-
domized trial comparing the heparin-bonded Viabahn-
covered stent versus BMS for the treatment of complex
femoropopliteal lesions. A total of 141 patients with symp-
tomatic peripheral arterial disease were assigned to treatment
with a Viabahn-covered stent or BMS. In the per-protocol
analysis, the 12-month primary patency rate was 78.1% in
the Viabahn group compared with 53.5% in the BMS group.
For lesions 20 cm, the apparent beneﬁt was even greater,
with a primary patency rate of 73.3% for Viabahn versus
33.3% for BMS. Serious adverse events were infrequent in
either treatment group, and importantly, the risk of stent
thrombosis and development of acute limb ischemia was not
increased by use of a covered stent.
The authors (9) are to be congratulated on successfully
conducting a randomized trial on a challenging subset of
patients that remains understudied. Although the results
generally support use of Viabahn-covered stents for long
femoropopliteal lesions, several aspects of the study should
be taken into consideration. First, 12 of the subjects (6 in
each group) who underwent randomization were considered
protocol violations. Most of the results are therefore reported
as per-protocol analysis. When the primary outcome was
analyzed by using intention-to-treat analysis, the difference
in 12-month primary patency between the Viabahn and the
noncovered stents was not statistically signiﬁcant. Second,
clinically driven target lesion revascularization rates did not
differ between groups, suggesting that the differences in
duplex-derived restenosis may not have translated into
differences in symptoms. Consistent with this ﬁnding, there
was no signiﬁcant difference between groups in walking
distance at 12 months.
The VIASTAR trial has shown that implantation of
a heparin-bonded covered stent is a reasonable treatment
strategy for patients with long-segment femoropopliteal
occlusive disease (9). These data conﬁrm what has been
known for some time: that the durability of femoropoplitealstenting with BMS is inversely related to lesion length.
However, patency after implantation of the Viabahn stent
graft seems to be independent of lesion length. Although the
advantage of a covered stent over a BMS is apparent for
these longer lesions, there is less certainty about the optimal
treatment of short- or medium-length lesions. Newer BMS,
drug-eluting stents, drug-coated balloons, and atherectomy
devices have all shown promise for these shorter lesions.
With the recent FDA approval of a paclitaxel-eluting stent,
there will also be questions about whether a drug-eluting
stent can provide results comparable to an ePTFE-covered
stent for longer femoropopliteal lesions. Perhaps covering
a stent with an antirestenotic drug is as effective as an
ePTFE barrier. For the time being, however, it does seem
that when it comes to stenting for the treatment of long-
segment femoropopliteal disease, it is better if our stents
are “covered up.”
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